A Phase 2, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Lixivaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Adverse reactions
- Acronyms ELISA
- Sponsors Palladio Biosciences
- 05 Nov 2019 According to Palladio Biosciences media release, data from this study will be presented at the American Society of Nephrologys Kidney Week 2019, to be held in Washington, D.C. on November 7-10.
- 22 Oct 2019 Planned End Date changed from 1 Sep 2019 to 1 Feb 2020.
- 22 Oct 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Jan 2020.